New insider activity at Viking Therapeutics ( (VKTX) ) has taken place on October 28, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a series of notable transactions, several key executives at Viking Therapeutics have sold significant portions of their stock. Director Charles Rowland led the sales by offloading 60,000 shares, amounting to $2,134,200. Following him, President & CEO Brian Lian sold 38,989 shares, garnering $1,364,615. CFO Greg Zante and COO Marianna Mancini each sold 6,185 shares, with both transactions valued at $216,475. These sales highlight a substantial reshuffling of shares among Viking Therapeutics’ top brass.
Recent Updates on VKTX stock
In the last 24 hours, Viking Therapeutics has been in the spotlight due to several developments. The company announced updates on its ongoing Phase 3 clinical trials for VK2735, a promising treatment for weight management in both diabetic and non-diabetic obese patients. These trials are progressing well, with the company reporting accelerated enrollment and positive Phase II results, which have bolstered investor confidence. However, the financial landscape is mixed; despite a strong cash position of $715 million, the company reported increased net losses due to heightened R&D expenses. This financial strain, coupled with potential regulatory risks from U.S. policy shifts, has led to a cautious market outlook. Consequently, JPMorgan adjusted its price target for Viking Therapeutics, reflecting these financial challenges and regulatory uncertainties. Overall, while the clinical progress is promising, the financial and regulatory environment poses significant challenges for the company.
Spark’s Take on VKTX Stock
According to Spark, TipRanks’ AI Analyst, VKTX is a Neutral.
Viking Therapeutics’ overall score reflects the typical profile of an early-stage biotech company. Strengths include a robust balance sheet and promising clinical trial results, but these are offset by high operational losses and cash burn. Technical indicators suggest short-term positive momentum, yet valuation concerns persist due to the absence of profitability. The earnings call provided a positive outlook with significant pipeline advancements.
To see Spark’s full report on VKTX stock, click here.
More about Viking Therapeutics
YTD Price Performance: -12.62%
Average Trading Volume: 6,465,890
Technical Sentiment Signal: Buy
Current Market Cap: $3.89B